MiR-200b与miR-155作为局部晚期头颈部鳞状细胞癌放化疗疗效的预测生物标志物
研究利用ARO-0401 III期试验中接受5-氟尿嘧啶/顺铂或5-氟尿嘧啶/丝裂霉素C放化疗的局部晚期头颈部鳞状细胞癌患者肿瘤标本,先在48例口咽癌测试队列中用微阵列和nanoString免疫面板筛选,再在149例头颈鳞癌患者中用实时PCR验证。miR-200b和miR-155在口咽癌中可预测放化疗疗效,但下咽癌中无此预测价值;miR-146a为两种方案的预后标志物。
要点
- 在口咽癌中,实时PCR验证miR-200b和miR-155可预测放化疗疗效,下咽癌中无此预测价值。
- miR-200b主要与远处转移相关,miR-155与局部复发相关。
- miR-146a为两种放化疗方案的预后标志物;miR-155和miR-146a为肿瘤浸润淋巴细胞的替代标志物。
核心结论
- MiR-200b和miR-155被确立为两种标准化疗放疗方案个体化治疗选择的潜在标志物;miR-155的预测作用值得进一步研究,尤其是在放化疗与免疫检查点抑制剂联合的临床试验框架内。
研究设计与样本
- 研究为在ARO-0401 III期试验框架内开展的生物标志物分析,肿瘤材料为福尔马林固定石蜡包埋组织,来自接受放疗联合5-氟尿嘧啶/顺铂(CDDP-CRTX)或5-氟尿嘧啶/丝裂霉素C(MMC-CRTX)的局部晚期头颈部鳞状细胞癌患者。
- 在48例口咽癌测试队列中,用Affymetrix miRNA微阵列和nanoString PanCancer免疫面板分别建立miRNA和免疫特征谱;在149例头颈鳞癌患者中用实时PCR检测候选miRNA表达。
- 用Kaplan-Meier和Cox回归分析判定miRNA谱与放化疗疗效的相互影响。
主要发现
- 5种miRNA(miR-27b、-130b、-200b、-451和-532-5p)的表达水平与MMC-CRTX后的总生存期显著相关。
- 6种不同miRNA(miR-125b、-146a、-150、-155、-187和-342-5p)与CDDP-CRTX后的总生存期相关。
- 实时PCR验证确认miR-200b和miR-155在口咽癌中的预测价值,该价值在下咽癌中不存在。
- miR-146a为两种放化疗方案的预后标志物;miR-200b表达主要与远处转移相关,而miR-155与局部复发相关。
- miR-155和miR-146a被确定为肿瘤浸润淋巴细胞的替代标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出miR-155的预测作用值得进一步研究,尤其是在放化疗与免疫检查点抑制剂联合的临床试验框架内。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The predictive value of microRNAs (miRNAs) in tumour cells and infiltrating immune cells for the efficacy of chemoradiation (CRTX) in locally advanced head and neck squamous cell carcinoma (HNSCC) was evaluated. METHODS: Formalin-fixed, paraffin-embedded tumour material was collected from patients with locally advanced HNSCC treated within the ARO-0401 phase III trial with radiotherapy in combination with either 5-fluorouracil/cisplatin (CDDP-CRTX) or 5-fluorouracil/mitomycin C (MMC-CRTX). MiRNA and immune profiles were established in a test cohort of 48 oropharyngeal carcinoma (OPSCC) cases by Affymetrix miRNA microarrays and the nanoString PanCancer Immune Panel, respectively. Expression of miRNA candidates was measured in 149 HNSCC patients by real-time PCR. Interference of miRNA profiles with CRTX efficacy was determined by Kaplan-Meier and Cox regression analysis. RESULTS: Expression levels of five miRNAs (miR-27b, -130b, -200b, -451 and -532-5p) were significantly associated with overall survival after MMC-CRTX. Six different miRNAs (miR-125b, -146a, -150, -155, -187 and -342-5p) were correlated with overall survival after CDDP-CRTX. Validation by real-time PCR confirmed the predictive value of miR-200b and miR-155 in OPSCC, which was absent in hypopharyngeal carcinomas. MiR-146a was revealed as a prognostic marker for both CRTX regimens. MiR-200b expression was mainly associated with distant metastasis, whereas miR-155 correlated with local recurrence. MiR-155 and miR-146a were identified as surrogate markers for tumour-infiltrating lymphocytes. CONCLUSIONS: MiR-200b and miR-155 were established as potential markers for personalised treatment selection of two standard regimens of CRTX. The predictive role of miR-155 deserves further investigation, especially within the framework of clinical trials of CRTX/immune checkpoint inhibitor combinations.
引用
- Hess AK, Müer A, Mairinger FD, et al. MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. Eur J Cancer. 2017. PMID: 28347920. doi:10.1016/j.ejca.2017.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。